COMPASS Pathways plc - 8-K Filing
Compass Pathways reported Q1 2026 net income of $91.2 million ($0.71 basic EPS) compared to a $17.9 million loss in the same period last year, driven by a $130.9 million non-cash gain on warrant fair value adjustments. The company ended March with $466 million in cash and plans for an NDA submission for COMP360 psilocybin treatment in TRD by Q4 2026. (Items: 2.02 of this Form 8-K (including Exhibit 99)
Tickers: $CMPS